K. Altundag Et Al. , "Adjuvant trastuzumab use in high-risk breast cancer patients may prevent development of contralateral estrogen receptor-negative breast tumors," MEDICAL HYPOTHESES , vol.66, no.5, pp.1045-1046, 2006
Altundag, K. Et Al. 2006. Adjuvant trastuzumab use in high-risk breast cancer patients may prevent development of contralateral estrogen receptor-negative breast tumors. MEDICAL HYPOTHESES , vol.66, no.5 , 1045-1046.
Altundag, K., Altundag, O., Islam, R., & Gundeslioglu, O., (2006). Adjuvant trastuzumab use in high-risk breast cancer patients may prevent development of contralateral estrogen receptor-negative breast tumors. MEDICAL HYPOTHESES , vol.66, no.5, 1045-1046.
Altundag, K Et Al. "Adjuvant trastuzumab use in high-risk breast cancer patients may prevent development of contralateral estrogen receptor-negative breast tumors," MEDICAL HYPOTHESES , vol.66, no.5, 1045-1046, 2006
Altundag, K Et Al. "Adjuvant trastuzumab use in high-risk breast cancer patients may prevent development of contralateral estrogen receptor-negative breast tumors." MEDICAL HYPOTHESES , vol.66, no.5, pp.1045-1046, 2006
Altundag, K. Et Al. (2006) . "Adjuvant trastuzumab use in high-risk breast cancer patients may prevent development of contralateral estrogen receptor-negative breast tumors." MEDICAL HYPOTHESES , vol.66, no.5, pp.1045-1046.
@article{article, author={K Altundag Et Al. }, title={Adjuvant trastuzumab use in high-risk breast cancer patients may prevent development of contralateral estrogen receptor-negative breast tumors}, journal={MEDICAL HYPOTHESES}, year=2006, pages={1045-1046} }